Vital KSK Holdings, Inc. (3151) AI Stock Analysis

• Market Cap: ¥58.58B
• Dividend Yield: 4.66%
• Average Volume (3M): 121.33K
• Price to Earnings (P/E): 9.0
• Beta (1Y): 0.46
• Revenue Growth: 2.22%
• EPS Growth: 21.19%
• Country: JP
• Employees: 3,705
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 14.36
• Shares Outstanding: 51,902,977
• 10 Day Avg. Volume: 69,970
• 30 Day Avg. Volume: 121,326
• PEG Ratio: 0.29
• Price to Book (P/B): 0.58
• Price to Sales (P/S): 0.10
• P/FCF Ratio: -5.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ¥1,340.00 ▲(7.72% Upside)

Vital KSK Holdings, Inc. scores well on valuation due to its low P/E ratio and high dividend yield, indicating potential undervaluation. However, technical analysis shows bearish momentum, and financial performance highlights operational and cash flow inefficiencies that need improvement. These factors collectively result in a moderate overall stock score.

Vital KSK Holdings, Inc. Business Overview & Revenue Model

Company Description

Vital KSK Holdings, Inc. engages in the wholesale of pharmaceutical products in Japan. The company is involved in the wholesale of veterinary drugs; agricultural chemicals, agricultural materials, etc.; and medical and nursing care equipment. It also engages in the pharmacy and nursing care businesses; transportation business; insurance agent and real estate management businesses; parking business; mail-order business of health-related products; and pharmacy dispensing business. In addition, the company offers medical management consulting services; and manufactures OTC drugs. The company was founded in 2009 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Vital KSK Holdings, Inc. generates revenue through several key streams, which include direct sales of its health products, subscription services for wellness programs, and partnerships with healthcare institutions. The company's direct-to-consumer sales model allows it to reach a wide customer base via online platforms and retail channels. Additionally, recurring revenue is generated from subscription services that offer personalized health plans and ongoing support. Strategic partnerships with healthcare providers and organizations further enhance the company's market presence, enabling it to tap into larger consumer segments and secure contracts for supplying medical devices and supplements, contributing significantly to its overall earnings.

Vital KSK Holdings, Inc. Financial Statement Overview

Summary

Vital KSK Holdings, Inc. shows steady revenue growth and a strong equity position, indicating stability and potential for future growth. However, operational inefficiencies and negative cash flow present challenges that need addressing to enhance profitability and liquidity.

Income Statement

Vital KSK Holdings, Inc. displays a steady revenue growth rate with a 2.18% increase from the previous year. The gross profit margin stands at 8.20%, which is relatively stable over the years. The net profit margin improved to 1.22%, indicating better profitability. However, the EBIT margin is 0.95%, showing limited operating efficiency. Overall, the company is on a positive growth trajectory but needs to enhance operational efficiency.

Balance Sheet

The company maintains a strong equity base with a debt-to-equity ratio of 0.08, indicating low leverage. The return on equity (ROE) is 6.90%, reflecting moderate returns to shareholders. With an equity ratio of 35.36%, Vital KSK Holdings has a stable financial structure. Despite the solid foundation, greater returns and asset utilization could augment shareholder value.

Cash Flow

Vital KSK Holdings faces challenges with its cash flow, marked by negative operating cash flow. The free cash flow is also negative, affecting liquidity. The operating cash flow to net income ratio is -1.10, indicating inefficiencies in converting income to cash. Improvement in cash management and operational efficiencies are vital for better financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	602.28B	600.37B	587.48B	579.77B	577.25B	537.06B
Gross Profit	49.38B	49.22B	48.30B	44.96B	43.98B	38.22B
EBITDA	10.79B	14.56B	12.16B	11.56B	10.87B	5.72B
Net Income	6.96B	7.31B	5.84B	4.83B	4.77B	1.17B
Balance Sheet
Total Assets	305.27B	299.43B	317.26B	297.32B	313.03B	311.40B
Cash, Cash Equivalents and Short-Term Investments	24.39B	23.10B	34.71B	19.03B	26.97B	29.78B
Total Debt	6.51B	8.59B	9.11B	10.25B	11.85B	16.80B
Total Liabilities	199.57B	192.12B	211.32B	197.15B	212.99B	207.49B
Stockholders Equity	104.29B	105.91B	104.66B	98.98B	98.96B	102.94B
Cash Flow
Free Cash Flow	0.00	-10.59B	18.47B	-9.60B	3.35B	-5.23B
Operating Cash Flow	0.00	-8.02B	23.57B	-3.00B	7.49B	-1.39B
Investing Cash Flow	0.00	3.52B	-1.82B	-1.04B	-2.01B	549.00M
Financing Cash Flow	0.00	-6.54B	-5.77B	-4.08B	-8.49B	-2.52B

Vital KSK Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1244.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3151, the sentiment is Neutral. The current price of 1244 is below the 20-day moving average (MA) of 1288.70, below the 50-day MA of 1274.99, and above the 200-day MA of 1213.38, indicating a neutral trend. The MACD of -7.50 indicates Positive momentum. The RSI at 40.21 is Neutral, neither overbought nor oversold. The STOCH value of 9.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3151.

Vital KSK Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9265	―	¥8.14B	14.81	―	1.91%	2.65%	8.83%
2689	―	¥12.45B	8.47	―	3.91%	3.49%	-4.39%
3183	―	¥37.44B	17.73	―	4.12%	5.81%	8.10%
3151	―	¥58.58B	9.01	―	4.66%	2.22%	21.19%
3593	―	$117.07B	95.31	0.78%	1.61%	-2.06%	-79.17%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4552	―	¥79.20B	―	―	3.47%	7.15%	-454.41%

Vital KSK Holdings, Inc. Corporate Events

Vital KSK Holdings Establishes New Pharma Subsidiary

Vital KSK Holdings, Inc. has announced the establishment of a new subsidiary, MedLeap Pharma Company Limited, which will focus on pharmaceutical research and development. The subsidiary is fully owned by Vital KSK Holdings and will be led by Yuichi Kobayashi, an executive officer of the parent company. The impact of this new subsidiary on the company’s financial results for the fiscal year ending March 2026 is expected to be minimal.

The most recent analyst rating on (JP:3151) stock is a Buy with a Yen1385.00 price target. To see the full list of analyst forecasts on Vital KSK Holdings, Inc. stock, see the JP:3151 Stock Forecast page.

Vital KSK Holdings Expands Pharmaceutical Operations with New Subsidiary

Vital KSK Holdings, Inc. has announced the establishment of a new subsidiary to further its pharmaceutical business operations, specifically to handle the development and commercialization of ACCRUFeR®, an iron deficiency treatment. This strategic move, following an exclusive license agreement with Shield Therapeutics, aims to strengthen the company’s position in the Japanese pharmaceutical market. The subsidiary will be fully owned by Vital KSK Holdings, with key personnel from the parent company taking leadership roles. The financial impact of this establishment is expected to be minimal for the fiscal year ending March 2026.

The most recent analyst rating on (JP:3151) stock is a Buy with a Yen1387.00 price target. To see the full list of analyst forecasts on Vital KSK Holdings, Inc. stock, see the JP:3151 Stock Forecast page.

Vital KSK Holdings Reports Q1 Financial Results with Decline in Profits

Vital KSK Holdings, Inc. reported its consolidated financial results for the first quarter ending June 30, 2025, showing a slight increase in net sales by 1.3% compared to the previous year. However, the company experienced a significant decline in profits, with operating profit down by 34.5% and ordinary profit decreasing by 33.1%. The company maintains its forecast for the fiscal year ending March 31, 2026, with expected net sales growth of 3.3% but anticipates a decline in operating and ordinary profits.